111087 ⎘
ssRNA viruses negative-sense; Details; Rhabdoviridae; Lyssavirus, e.g. rabies virus Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION
#2COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF RABIES VIRUS INFECTION
#3RABIES G PROTEIN AND USES THEREOF
#4SIGNAL SEQUENCES FOR NUCLEIC ACID VACCINES
#5Chimeric Flavivirus Lyssavirus Vaccines
#6ENGINEERED RABIES VIRUS GLYCOPROTEIN, COMPOSITIONS, AND METHODS OF USE THEREOF
#7MODIFIED ALPHAVIRUSES WITH HETEROLOGOUS NONSTRUCTURAL PROTEINS
#8NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE
#9GENE SHUFFLED LYSSAVIRUS VACCINE
#10ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION
#11CORONAVIRUS VACCINE COMPOSITIONS AND METHODS OF USE
#12Composition comprising PIC for treatment of cancer
#13Methods of producing and characterizing virus vaccine and virus vaccine composition
#14Artificial nucleic acid molecules for improved protein expression
#15Rabies vaccine
#16Adenovirus polynucleotides and polypeptides
#17RNA CONSTRUCT
#18NOVEL LYSSA VIRUS PHOSPHOPROTEINS
#19CHIMPANZEE ADENOVIRUS CONSTRUCTS WITH LYSSAVIRUS ANTIGENS
#20Artificial nucleic acid molecules for improved protein expression
#21Multivalent vaccines for rabies virus and coronaviruses
#22Rabies composition comprising PIKA adjuvant
#23Artificial nucleic acid molecules for improved protein expression
#24Chimeric flavivirus lyssavirus vaccines
#25Apparatus for releasably holding a socket
#26CHIMPANZEE ADENOVIRUS CONSTRUCTS WITH LYSSAVIRUS ANTIGENS
#27Replication competent adenoviral vectors
#28Compositions and administration of chimeric glycoprotein lyssavirus vaccines for coverage against rabies
#29VIRUS LIKE PARTICLE PRODUCTION IN PLANTS
#30SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER
#31Parainfluenza virus 5 based vaccines
#32Rabies vaccine
#33Apparatus for releasably holding a socket
#34Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
#35METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE RESPONSES
#36Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
#37Adenovirus polynucleotides and polypeptides
#38Methods of producing and characterizing virus vaccine and virus vaccine composition
#39RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPS)
#40Method for increasing expression of RNA-encoded proteins
#41Composition comprising PIC for treatment of cancer
#42Multivalent vaccines for rabies virus and coronaviruses
#43Methods of producing and characterizing virus vaccine and virus vaccine composition
#44Human antibodies against rabies and uses thereof
#45Compositions and methods for treating viral infections
#46Vaccine adjuvant composition comprising inulin particles
#47Compositions containing ambient-temperature stable, inactivated but therapeutically active biopharmaceuticals and methods for formulation thereof
#48Canine adenovirus vectors
#49Artificial nucleic acid molecules for improved protein expression
#50Rabies glycoprotein virus-like particles (VLPS)
#51A Rabies Composition Comprising Pika Adjuvant
#52PIV5 as an oncolytic agent
#53Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
#54Production of recombinant expression vectors
#55SMC combination therapy for the treatment of cancer
#56Vaccination response for immunodeficiency disorders or high cortisol
#57Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
#58COMPOSITIONS CONTAINING AMBIENT-TEMPERATURE STABLE, INACTIVATED BUT THERAPEUTICALLY ACTIVE BIOPHARMACEUTICALS & METHODS FOR FORMULATION THEREOF
#59Parainfluenza virus 5 based vaccines
#60Nasal mucosal vaccine composition
#61Mucosal vaccine composition
#62Rabies vaccine
#63Method for increasing expression of RNA-encoded proteins
#64Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
#65Compositions containing ambient-temperature stable, inactivated but therapeutically active biopharmaceuticals and methods for formulation thereof
#66Methods of generating robust passive and active immune responses
#67ASSAY FOR ANALYSES OF RABIES VIRUS GLYCOPROTEIN
#68Method for purifying the rabies virus
#69Immunization with rabies virus vector expressing foreign protein antigen
#70Vaccination response for immunodeficiency or high cortisol
#71Isolated nucleic acid for the production of a vaccine against virus
#72PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN
#73Parainfluenza virus 5 based vaccines
#74Prion disease-specific epitopes and methods of use thereof
#75PIV5 as oncolytic agent
#76COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
#77Multivalent vaccines for rabies virus and filoviruses
#78Rabies glycoprotein virus-like particles (VLPS)
#79Stabilizing excipient for inactivated whole virus vaccine
#80Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
#81Method for reducing DNA impurities in viral compositions
#82Pan-lyssavirus vaccines against rabies
#83Adjuvanted rabies vaccine with improved viscosity profile
#84Transcutaneous immunization without heterologous adjuvant
#85Replication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus
#86COMPOSITION
#87Simian Adenovirus Vectors and Methods of Use
#88PARAPOXVIRUS VECTORS
#89RABIES VACCINE
#90Farnesoid-X-receptor antagonist as a vaccine adjuvant
#91Rabies virus-based recombinant immunocontraceptive compositions and methods of use
#92Replication-defective flavivirus vaccines and vaccine vectors
#93Stabilizing excipient for inactivated whole virus vaccine
#94Rabies virus vector systems and compositions and methods thereof
#95Attenuated live triple G protein recombinant rabies virus vaccine for pre- and post-exposure prophylaxis of rabies
#96RABIES CURE
#97Polyinosinic acid-polycytidylic acid-based adjuvant
#98Rabies Vaccine
#99Method for purifying the rabies virus
#100Adaptation of Pitman Moore strain of rabies virus to primary chick embryo fibroblast cell cultures
#101Rabies vaccine
#102Simian adenovirus vectors and methods of use
#103Dry Formulation for Transcutaneous Immunization
#104Cationic lipid-mediated enhancement of nucleic acid immunization of cats
#105Raccoon poxvirus expressing rabies glycoproteins
#106Chimeric G protein based rabies vaccine
#107Rhabdoviral N-Fusion Proteins as Carrier for Foreign Antigens
#108Rabies virus vector systems and compositions and methods thereof
#109Use of penetration enhancers and barrier disruption methods to enhance the immune response of an antigen
#110Chimeric lyssavirus nucleic acids and polypeptides
#111Medicine for Treating Tumor and Use Therefor in Preparation of the Medicaments for Treating Tumor
#112Use of penetration enhancers and barrier disruption methods to enhance the immune response of antigen and adjuvant
#113Immunologically enhanced recombinant vaccines
#114Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the CNS
#115Polyinosinic acid-polycytidylic acid-based adjuvant
#116Rabies vaccine
#117Antigenic peptides of rabies virus and uses thereof
#118Compositions and methods for delivery of genetic material
#119Methods for inducing an immune response via oral administration of an adenovirus
#120Use of modified novirhabdoviruses to obtain vaccines
#121Chimeric adenoviruses
#122Transcutaneous immunization without heterologous adjuvant
#123Vaccination of skunks and/or mongooses against rabies
#124Chimeric lyssavirus nucleic acids and polypeptides
#125Cationic lipid-mediated enhancement of nucleic acid immunization of cats